Kindred shakes shareholder lawsuit, pushes forward with Humana deal

Legal and regulatory issues
A Delaware court denied a motion for a preliminary injunction against Humana's acquisition of Kindred. (iStock/BCFC)

A Delaware court has denied a preliminary injunction sought by a top Kindred Healthcare shareholder to block a pending $4.1 billion deal with Humana, allowing the takeover to move forward.

The Delaware Court of Chancery dismissed the motion for injunction filed by hedge fund Brigade Capital Management at the beginning of the month, Kindred said in an announcement. However, the court stipulated that Kindred must open stockholder voting for five business days.

“We are pleased that the Court has denied all of the relief Brigade sought,” the company said in a statement. “As we have maintained, the Kindred Board of Directors acted in accordance with its fiduciary duties and in the best interests of all stockholders throughout the entirety of its 18-month-long process to maximize stockholder value. We continue to expect to complete the transaction this summer and look forward to providing Kindred’s stockholders with premium cash value for their investment.”


2019 Drug Pricing and Reimbursement Stakeholder Summit

Given federal and state pricing requirements arising, press releases from industry leading pharma companies, and the new Drug Transparency Act, it is important to stay ahead of news headlines and anticipated requirements in order to hit company profit targets, maintain value to patients and promote strong, multi-beneficial relationships with manufacturers, providers, payers, and all other stakeholders within the pricing landscape. This conference will provide a platform to encourage a dialogue among such stakeholders in the pricing and reimbursement space so that they can receive a current state of the union regarding regulatory changes while providing actionable insights in anticipation of the future.

Brigade Capital issued a quick rebuttal in the lead-up to the vote which began Thursday morning, calling Kindred’s statement that the court denied all relief “misleading,” and urging stockholders to vote “no” on the proposed acquisition.

RELATED: Humana emphasizes ‘robust data sharing,’ analytics and digital tools in Kindred acquisition

Brigade has been critical of the deal, in which Humana and two private equity firms have agreed to buy the long-term care provider, arguing that the $9-per-share price is well below market value. The firm claims Kindred’s board never attempted to increase the price after the Centers for Medicare & Medicaid Services pulled back on a proposed rule that would have cut home health spending by $950 million, “a significant headwind that was in fact a basis for the buyer group to lower its bid.”

RELATED: Humana, pair of private equity firms will buy Kindred Healthcare for $4.1B

“We simply cannot get our heads around this fact,” Brigade said in a statement on Wednesday.

Humana, which will own a 40% stake in Kindred if the deal is approved, has said “robust data sharing” between the two companies will improve predictive modeling for home health patients and allow the insurer to leverage digital tools like remote monitoring and telehealth.  

Suggested Articles

We need our federal programs and policies to reflect the goal of improving the health of both women and men.

Two lawsuits were filed suing the Trump administration to overturn a new rule that would allow healthcare workers to deny care over religious or conscience…

Policy changes are affecting how investors view the skilled home health market and paving the way for potential strategic acquisitions.